Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune response to antigens admixed therewith. In embodiments, the steroid acid may be a bile acid and the peptide may comprise one or more functional domains, such as a nuclear localization signal, which may facilitate antigen-presentation and/or antigen cross-presentation, thereby triggering improved cellular immunity, or improved cellular and humoral immunity, against the antigen.

Provided are methods of making and delivering vaccine compositions using an enucleated cell-based platform. Methods of clearing pathogenic infections in a subject using the enucleated cell-based platform is also provided. Such enucleated cell-based platform reduces the vaccine development timeline as compared with conventional biological vaccines, and improves vaccine efficacy.

The present invention relates to the treatment of autoimmune and allergic diseases by oromucosal administration of a formulation consisting of an optimized combination of antigen, tolerizing agent and mucoadhesive carrier for each immune disease indication.

The present disclosure provides particles for delivering a nucleic acid that encodes an immunogenic peptide in an antigen presenting cell. The disclosed particles can function as a vaccine and can be used to treat or prevent a viral or bacterial infection in a subject by expressing in vivo an immunogenic peptide, thereby stimulating the subject's immune system to attack the virus or bacteria that naturally express the immunogenic peptide.

Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune response to antigens admixed therewith. In embodiments, the steroid acid may be a bile acid and the peptide may comprise one or more functional domains, such as a nuclear localization signal, which may facilitate antigen-presentation and/or antigen cross-presentation, thereby triggering improved cellular immunity, or improved cellular and humoral immunity, against the antigen.

Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune response to antigens admixed therewith. In embodiments, the steroid acid may be a bile acid and the peptide may comprise one or more functional domains, such as a nuclear localization signal, which may facilitate antigen-presentation and/or antigen cross-presentation, thereby triggering improved cellular immunity, or improved cellular and humoral immunity, against the antigen.

Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.

A delivery system for delivering water-soluble components and water-insoluble components of whole-cell components using nano-sized or micro-sized particles, and a use of which in preparing vaccines for preventing and treating cancer. The whole-cell components delivery system consisting of a nano-sized or micron-sized particle and whole-cell components loaded on the particle, the whole-cell components are water-soluble components and water-insoluble components of a whole cell in a cell or tissue. The mutated proteins or peptides produced by cancer in cellular components are loaded on nanoparticles or micronparticles. These immunogenic substances generated by mutations in disease in whole-cell components can be used for cancer prevention and treatment and preparing vaccines for preventing and/or treating cancer.

The present disclosure relates to modified extracellular vesicles, e.g., exosomes, comprising a targeting moiety, wherein the targeting moiety can specifically bind to markers expressed on distinct immune cells (e.g., dendritic cells). Also provided herein are methods for using the exosomes to treat and/or prevent a range of medical disorders.

The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the α-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.